MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze VTRS →
    • FindStock Picks / Stock Screener
    • Value · VTRSIntrinsic Value Calculator
    • Invest · VTRSInvestment Case
    • Hold · VTRS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
VTRS stock logo

VTRS

Viatris Inc.

$20.82
0.15
 (0.73%)
Exchange:  NASDAQ
Market Cap:  23.869B
Shares Outstanding:  1.171B
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – Specialty & GenericView industry performance
   
CEO:  Scott Andrew Smith
Full Time Employees:  30000
Address: 
Robert J. Coury Global Center
Canonsburg
PA
15317
US
Website:  https://www.viatris.com
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris’s APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company’s extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
VTVTRS logoVTRSViatris Inc.23.9B—8.1-0.3%
ZTZTS logoZTSZoetis Inc.34.1B14.213.320.9%
ELELAN logoELANElanco Animal Health Incorporated13.4B—22.94.4%
RDRDY logoRDYDr. Reddy's Laboratories Limited12.3B41.123.14.8%
ALALKS logoALKSAlkermes plc7.9B15,677—-0.1%
HLHLN logoHLNHaleon plc40.2B19.016.56.5%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue15,426,90014,739,30014,299,900
Gross Profit6,438,6005,623,6005,013,500
EBITDA3,516,5002,635,300-395,400
Operating Income766,20010,100-2,663,100
Net Income54,700-634,200-3,514,900

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets47,685,50041,500,90037,193,100
Total Liabilities27,218,10022,865,40022,481,800
Total Stockholders Equity20,467,40018,635,50014,711,300
Total Debt18,371,20014,305,90014,413,900
Cash and Cash Equivalents991,900734,8001,322,400

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,799,6002,302,9002,315,900
Capital Expenditure-474,500-326,000-378,800
Free Cash Flow2,325,1001,976,9001,937,100
Net Income54,700-634,200-3,514,900
Net Change in Cash-268,900-257,500611,900

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)16,662,620.940Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)17,036,017.441Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)16,876,000Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)6,345,524.660Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)6,480,062.616Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)6,422,405.599Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)3,650,113.826Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)3,756,869.959Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)3,711,119.003Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)4,589,573.440Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)4,692,422.245Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)4,648,346.839Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)3.170Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)3.210Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)3.120Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
14.71B  ?P/S
 (TTM)
: 
1.62
?Net Income
 (TTM)
: 
-634.2M  ?P/E
 (TTM)
: 
-39.28
?Enterprise Value
 (TTM)
: 
35.662B  ?EV/FCF
 (TTM)
: 
17.47
?Dividend Yield
 (TTM)
: 
2.31%  ?Payout Ratio
 (TTM)
: 
-91.33%
?ROE
 (TTM)
: 
-4.24%  ?ROIC
 (TTM)
: 
-0.26%
?Net Debt
 (TTM)
: 
13.484B  ?Debt/Equity
 (TTM)
: 
0.99
?P/B
 (TTM)
: 
1.75  ?Current Ratio
 (TTM)
: 
1.55

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
8.13Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates VTRS intrinsic value between $20.78 – $25.30 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate VTRS Intrinsic Value

Common questions about VTRS valuation

Is Viatris Inc. (VTRS) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Viatris Inc. (VTRS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is VTRS a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether VTRS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is VTRS’s P/E ratio?

You can see VTRS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for VTRS?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is VTRS a good long-term investment?

Whether VTRS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Viatris Inc.

  • Viatris Inc. intrinsic value calculatorEstimate what the business is worth
  • Viatris Inc. 5-year outlookWhat has to go right, and what could go wrong
VTRS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.73
MarketSnap

Trading Metrics:

Open: 20.74   Previous Close: 20.67
Day Low: 20.39   Day High: 20.87
Year Low: 10.15   Year High: 21.2
Price Avg 50: 18.03   Price Avg 200: 16.2
Volume: 6.513M   Average Volume: 9.295M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Viatris Inc. (VTRS) Hit a 52 Week High, Can the Run Continue?
10-11-2026 10:15
Viatris Inc. (VTRS) Hit a 52 Week High, Can the Run Continue?
Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript
05-11-2026 13:34
Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript
Viatris (VTRS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
04-11-2026 10:16
Viatris (VTRS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
27-10-2026 13:11
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
16-10-2026 16:05
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
29-09-2026 14:00
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze VTRS →
    • FindStock Picks / Stock Screener
    • Value · VTRSIntrinsic Value Calculator
    • Invest · VTRSInvestment Case
    • Hold · VTRS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.